Premium
Regulatory peptides and systems biology: A new era of translational and reverse‐translational neuroendocrinology
Author(s) -
Eiden Lee E.,
Gundlach Andrew L.,
Grinevich Valery,
Lee Mary R.,
Mecawi André S.,
Chen Duan,
Buijs Ruud M.,
Hernandez Vito S.,
Fajardo-Dolci Germán,
Zhang Limei
Publication year - 2020
Publication title -
journal of neuroendocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.062
H-Index - 116
eISSN - 1365-2826
pISSN - 0953-8194
DOI - 10.1111/jne.12844
Subject(s) - biology , neuroendocrinology , translational research , drug discovery , translational medicine , ghrelin , drug development , neuroscience , computational biology , receptor , bioinformatics , pharmacology , endocrinology , drug , hormone , genetics , microbiology and biotechnology
Recently, there has been a resurgence in regulatory peptide science as a result of three converging trends. The first is the increasing population of the drug pipeline with peptide‐based therapeutics, mainly in, but not restricted to, incretin‐like molecules for treatment of metabolic disorders such as diabetes. The second is the development of genetic and optogenetic tools enabling new insights into how peptides actually function within brain and peripheral circuits to accomplish homeostatic and allostatic regulation. The third is the explosion in defined structures of the G‐protein coupled receptors to which most regulatory peptides bind and exert their actions. These trends have closely wedded basic systems biology to drug discovery and development, creating a “two‐way street” on which translational advances travel from basic research to the clinic, and, equally importantly, “reverse‐translational” information is gathered, about the molecular, cellular and circuit‐level mechanisms of action of regulatory peptides, comprising information required for the fine‐tuning of drug development through testing in animal models. This review focuses on a small group of ‘influential’ peptides, including oxytocin, vasopressin, pituitary adenylate cyclase‐activating polypeptide, ghrelin, relaxin‐3 and glucagon‐like peptide‐1, and how basic discoveries and their application to therapeutics have intertwined over the past decade.